Diabetic microangiopathy: IGFBP control endothelial cell growth by a common mechanism in spite of their species specificity and tissue peculiarity

Journal of Endocrinological Investigation

Volumn 29, Issue 8, 2006, Pages 754-763

  Giannini, S ^a   Cresci, B ^a   Manuelli, C ^a   Pala, L ^a   Rotella, C M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Endothelial cells; IGFBP; Microangiopathy

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR; MESSENGER RNA; OCTREOTIDE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN RECEPTOR;

CELL GROWTH; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLOMERULUS FILTRATION; HUMAN; HYPERGLYCEMIA; KIDNEY HYPERTROPHY; LASER COAGULATION; MICROALBUMINURIA; MITOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RETINA HEMORRHAGE; RETINA NEOVASCULARIZATION; REVIEW; SPECIES DIFFERENCE; VASCULAR SMOOTH MUSCLE;

EID: 33751038679     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344189     Document Type: Review

References (67)

1. Cines DB, Pollack ES, Buck CA, et al. Endothelial cells in physiology and in the pathophisiology of vascular disorders. Blood 1998, 91: 3527-61.
2. Schalkwijk CG, Stehouwer CDA. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clinical Science 2005, 109: 143-59.
3. Calles-Escadon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22: 36-52.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414: 813-20.
5. Takata K, Kasahara T, Kasahara M, et al. Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT-1) in cells of the blood-retinal barrier in the rat. Invest Opthalmol Vis Sci 1992, 33: 377-83.
6. Rotella CM, Giannini S, Galli G, et al. Role of endothelial cells in the pathogenesis of diabetic microangiopathy. Diab Nutr Metab 1996, 9: 273-89.
7. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction; a comprehensive appraisal. Cardiovascular diabetology 2006, 5: 4-22.
8. Grant M, King GL. IGF-I and blood vessels. Endocr Rev 1995, 3: 113-28.
9. Holt RIG, Simpson HL, Sonksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 2003, 20: 3-15.
10. Sonksen PH, Russell-Jones D, Jones RH. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future? Horm Res 1993, 40: 68-79.
11. Shaw LC, Grant MB. Insulin-like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. Rev Endocr Metab Discord 2004, 5: 199-207.
12. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004, 25: 971-1010.
13. Cummings EA, Sochett EB, Dekker MG, et al. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes 1998, 47: 1341-6.
14. Pedersen MM, Christensen SE, Christiansen JS, et al. Acute effect of a somatostatin analogue on kidney function in type 1 diabetic patients. Diabet Med 1990, 7: 304-9.
15. Flyvbjerg A, Bennett WF, Rasch R, et al. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999, 48: 377-82.
16. Daughaday WH, Rotwein P. Insulin-like growths factors-I and -II: peptide, messenger ribonucleid acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989, 110: 68-91.
17. Russell JW, Feldman EL. Insulin-like growths factors-I prevents apoptosis in sympathetic neurons exposed to high glucose. Horm Metab Res 1999, 31:90-6.
18. Nakae J, Kido J, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001, 22: 818-35.
19. Shimasaki S, Ling N. Identification and molecular characterization of insulin-like growth factor binding protein (IGFBP-1, -2, -3, -4, -5, and -6). Prog Growth Factor Res 1991, 3: 243-66.
20. Schneider MR, Lahm H, Wu M, et al. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. FASEB J 2000, 14: 629-40.
21. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002, 23: 824-54.
22. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002, 175: 19-31.
23. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P. Insulin-like growths factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog Growth Factor Res 1995, 6: 273-84.
24. Sakai K, Busby WH Jr, Clarke JB, Clemmons DR. Tissue transglutaminase facilitates the polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) and leads to loss of IGFBP-1's ability to inhibit insulin-like growth factor-I-stimulated protein synthesis. J Biol Chem 2001, 276: 8740-5.
25. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999, 20: 761-87.
26. Oh Y, Rosenfeld RG. Old and new concepts of insulin-like growths factors binding proteins. J Endocrinol Invest 1998, 21: 86-92.
27. Di Mario U, Pugliese G. 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Diabetologia 2001, 44: 674-92.
28. Delafontaine P, Song YH, Li Y. Expression, regulation and function of IGF-I, IGF-IR and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004, 24: 435-44.
29. Chisalita SI, Arnqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Am J Physiol 2004, 286: 896-901.
30. Petley T, Graff K, Jiang W, et al. Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm Metab Res 1999, 31: 70-6.
31. Ruberte J, Ayuso E, Navarro M, et al. Increased ocular levels of IGF-I in transgenic mice lead to diabetes-like eye disease. J Clin Invest 2004, 113: 1149-57.
32. Janssen JAMJL, Lamberts SWJ. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) 2000, 52:1-9.
33. Giannini S, Cresci B, Pala L, et al. IGFBPs modulate IGF-I- and high glucose-controlled growth of human retinal endothelial cells. J Endocrinol 2001, 171: 273-84.
34. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment of neovascularization. Regul Pept 1993, 48: 267-78.
35. Smith LEH, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999, 5: 1390-5.
36. Castellon R, Hamdi HK, Sacerio I, Aoki AM, Kenney MC, Ljubimov AV. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 2002, 74: 523-35.
37. Edwards EK, Ghiasuddin SM, Schepper AN, Yunger LM, Kelley KW. Newly defined property of somatotropin: priming macrophages for production of superoxide anion. Science 1988, 239: 769-71.
38. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992, 90: 439-46.
39. Pricci F, Pugliese G, Romano G, et al. Insulin-like growth factor I and II stimulate extracellular matrix production in human glomerular mesangial cells comparison with transforming growth factor-β. Endocrinology 1996, 137: 879-84.
40. Zhang GH, Ichimura T, Wallin A, Kann M, Stevens JL. Regulation of rat proximal tubule epithelial cell growth by fibroblast growth factors, insulin-like growth factor-1 and transforming growth factor-beta, and analysis of fibroblast growth factors in rat kidney. J Cell Physiol 1991, 148: 295-305.
41. Giannini S, Cresci B, Pala L, et al. Human glomerular endothelial cells IGFBPs are regulated by IGF-I and TGF-β1. Mol Cell Endocrinol 1999, 154: 123-36.
42. Ohashi H, Rosen KM, Smith FE, Villa-Komaroff L, Nayak RC, King GL. Characterization of type I IGF receptor and IGF-I mRNA expression in cultured human and bovine glomerular cells. Regul Peptide 1993, 48: 9-20.
43. Craig LE, Spelman JP, Strandberg JD, Zink MC. Endothelial cells from diverse tissues exhibit differences in growth and morphology. Microvasc Res 1998, 55: 65-76.
44. Delafontaine P, Ku L, Anwar A, Hayzer DJ. Insulin-like growth factor-I gene expression in vascular cells. Hypertension 1991, 17: 693-9.
45. Kudo FA, Warycha B, Juran PJ, et al. A differential responsiveness of early- and late-passage endothelial cells to shear stress. Am J Surg 2005, 190: 763-9.
46. Barr RS, Siddle K, Dolash S, Boes M. Actions of insulin and insulin-like growth factor-I and -II in cultured microvessels endothelial cells from bovine adipose tissue. Metabolism 1988, 37: 714-20.
47. Taylor WR, Nerem RM, Alexander RW. Polarized secretion of IGF-I and IGF-I binding protein activity by cultured aortic endothelial cells. J Cell Physiol 1993, 154: 139-42.
48. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-I promote rat aortic angiogenesis in vitro. Am J Pathol 1994, 145: 1023-9.
49. Giannini S, Cresci B, Manuelli C, et al. Insulin-like growth factor binding protein production in bovine retinal endothelial cells. Metabolism 1997, 46: 1367-79.
50. Yang YWH, Pioli P, Fiorelli G, Brandi ML, Rechler MM. Cyclic adenosine monophosphate stimulates insulin-like growth factor binding proteins-4 and its messenger ribonucleic acid in a clonal endothelial cell line. Endocrinology 1993, 133: 343-50.
51. Spoerri PE, Caballero S, Wilson SH, Shaw LC, Grant MB. Expression of IGFBP-3 by human retinal endothelial cells cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest Ophthalmol Vis Sci 2003, 44: 365-9.
52. Huang SS, Huang JS. TGF-β control of cell proliferation. J Cell Biochem 2005, 96: 447-62.
53. Booth BA, Boes M, Andress DL, et al. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 1995, 5: 1-17.
54. McKusker RH, Clemmonds DR. Use of lanthanum to accurately quantify insulin-like growth factor binding to proteins on cell surface. J Cell Biochem 1997, 66: 256-67.
55. Erondu NE, Dake BL, Moser DR, Lin M, Boes M, Bar RS. Regulation of endothelial IGFBP-3 synthesis and secretion by IGF-I and TGF-β. Growth Regul 1996,6:1-9.
56. Liu LQ, Sposato M, Liu HY, et al. Functional cloning of IGFBP-3 from human microvascular endothelial cells reveals its novel role in promoting proliferation of primitive CD34+CD38+ hematopoietic cells in vitro. Oncol Res 2003, 13: 359-71.
57. Schmid MC, Bisoffi M, Wetterwald A, et al. Insulin-like growth factor binding protein-3 is overexpressed in endothelial cells of mouse breast tumor vessels. Int J Cancer 2003, 103: 577-86.
58. Fraser HM, Lunn SF, Kim H, Erickson GF. Insulin-like growth factor binding protein-3 mRNA expression in endothelial cells of the primate corpus luteum. Human Reprod 1998, 13: 2180-5.
59. Granata R, Trovato L, Garbarino G, et al. Dual effects of IGFBP-3 on endothelial cells apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J 2004, 18: 1456-8.
60. Moser DR, Lowe WL Jr, Dake BL, Booth BA, Boes M. Endothelial cells express insulin-like growth factor-binding proteins 2 to 6. Mol Endocrinol 1992, 6:1805-14.
61. Bar RS, Booth BA, Boes M, Dake BL. Insulin-like growth factor binding protein from vascular endothelial cells: purification, characterization and intrinsic biological activities. Endocrinology 1989, 125: 1910-20.
62. Wood AW, Schlueter PJ, Duan C. Targeted knockdown of insulin-like growth factor binding protein-2 disrupts cardiovascular development in zebrafish embryos. Mol Endocrinol 2005, 19: 1024-34.
63. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997, 8: 45-62.
64. Booth BA, Boes M, Dake BL, Caldwell EE, Weiler JM, Bar RS. Effect of IGFBP-derived peptides on incorporation of (35)SO(4)into proteoglycans. Growth Horm IGF Res 2000, 10: 224-9.
65. Hewett P, Popplewell A, Finney H, Murray JC. Changes in microvessel endothelial cell gene expression in an in vitro human breast tumor endothelial cell model. Angiogenesis 1999, 3: 221-9.
66. Mohan S, Nakao Y, Honda Y, et al. Studies on the mechanism by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 1995, 270: 20424-31.
67. Ewton DZ, Coolican SA, Mohan S, Chrnausek SD, Florini JR. Modulation of insulin-like growth factor actions in L6A1 myoblasts by insulin-like growth factor binding proteins (IGFBP)-4 and IGFBP-5: a dual role for IGFBP-5. J Cell Physiol 1998, 177: 47-57.